Bayer Healthcare Pharmaceuticals has reported substantial progress during the latest status conference for the multidistrict litigation (MDL) No. 2100 regarding Yaz and Yasmin lawsuits. The status conference took place early in November 2015. It was presided over by U.S. District Judge David R. Herndon of the Southern District of Illinois.... Read more »

A Philadelphia jury has ordered Janssen Pharmaceuticals — a Johnson & Johnson subsidiary — to pay $1.8 million to a man who developed breasts while taking the pharmaceutical giant’s antipsychotic drug Risperdal. Jurors determined that the company knew the prescription medication could trigger atypical breast growth, but failed to properly... Read more »

As concern over risks associated with the type 2 diabetes drug Invokana continues to rise, a new study has shown the same dangers seen with the drug in type 2 diabetes patients may also be present in those with type 1 diabetes. Researchers have found that off-label use of this... Read more »

The first bellwether trials in multidistrict litigation 2545, which concerns injuries allegedly caused by testosterone replacement therapy, are slated to go to trial by fall of 2016. Court dockets show that more than 2,700 complaints are currently pending against the manufacturers of Testim, Adroderm, Androgel, Axiron and other products that... Read more »

A Louisiana mother has filed a Zofran lawsuit against GlaxoSmithKline on behalf of her son. Zofran (ondansetron) is a prescription medication used to prevent nausea and vomiting in chemotherapy or radiation patients. It is also commonly used by pregnant women suffering from morning sickness, though it has not received approval... Read more »

A plaintiff who filed a lawsuit against multiple manufacturers of testosterone therapy products claims use of Testim and Androgel led to his heart attack in 2013. The plaintiff has joined more than 3,000 other plaintiffs with similar allegations. Those lawsuits have been coordinated into multidistrict litigation in Illinois District Court. The plaintiff... Read more »

London-based AstraZeneca failed to obtain FDA approval for a proposed diabetes drug that combines two different medications, saxagliptin and dapagliflozin. In October 2015, the FDA issued a complete response letter to the pharmaceutical giant’s application. The agency requested additional clinical research on the proposed combination drug. AstraZeneca recently released statements... Read more »

A new report from the Project on Government Oversight (POGO) includes serious criticisms of the FDA and the process through which it approved Pradaxa, Boehringer Ingelheim’s widely used, yet highly controversial anticoagulant drug. The comprehensive review of Pradaxa’s path to the American market accuses the regulatory agency of being “lax,... Read more »

A federal judge has issued an order to remand three talc-related cancer lawsuits back to Missouri state court. The lawsuits represent 237 plaintiffs who claim that their diagnoses of ovarian cancer were linked to their use of talcum powder products. In October 2015, U.S. District Judge Catherine Perry rejected the... Read more »

Known as a sodium-glucose cotransporter-2, the blockbuster diabetes drug Invokana has been flying off the shelves, launching it to the top of the class of drugs also including Farxiga, Jardiance, Xigduo XR and Glyxambi. The drug presents a new and innovative way to treat the presence of glucose in the... Read more »